QR Code

A cluster randomized trial of Visitect CD4 Advanced Disease platform among outpatients with advanced HIV disease in Uganda

Abstract Introduction Despite significant progress in HIV care globally, a persistent 30–40% of people present with advanced HIV disease with ≤200 CD4 cells/µl. The Visitect CD4 Advanced Disease platform is a point‐of‐care CD4 test being implemented in resource‐limited settings. We sought to assess...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Elizabeth Nalintya, Elizabeth L. Schwartz, Patricia Nerima, Ann Fieberg, Sarah M. Najjuka, Ruth E. Ajilong, Tessa Adzemovic, Olive Namakula, Atukunda Mucunguzi, Kiiza Kandole Tadeo, Mark Oilor, Preethiya Sekar, Alice Lehman, Bruce Larson, Biyue Dai, David B. Meya, David R. Boulware, Radha Rajasingham, the ENCORE team
Hōputu: Artigo
Reo:Inglês
I whakaputaina: Wiley 2026-01-01
Rangatū:Journal of the International AIDS Society
Ngā marau:
advanced HIV disease
opportunistic infections
point‐of‐care
CD4 count
Visitect
Urunga tuihono:https://doi.org/10.1002/jia2.70075
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite